USA flag logo/image

An Official Website of the United States Government

Obese diabetic rat model w/o leptin/leptin-receptor defe

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
79966
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
DK074242
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PRECLINOMICS, INC.
7918 ZIONSVILLE RD INDIANAPOLIS, IN -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: Obese diabetic rat model w/o leptin/leptin-receptor defe
Agency: HHS
Contract: 1R43DK074242-01A1
Award Amount: $147,941.00
 

Abstract:

DESCRIPTION (provided by applicant): An estimated 18.2 million people (6.3 percent of the population) in the United States have diabetes; 90 to 95 percent of all diagnosed cases are type II diabetes (NIDDK, 2005). The search for new and more effective therapies to address the growing number of Americans with type II diabetes and related conditions is currently hindered by the lack of a research animal model that closely resembles the human diabetic condition. All rat models currently available commercially, related to metabolic syndrome and overt type II diabetes, have a genetic defect in leptin-receptor. On the contrary, leptin and leptin-receptor defects are not common causes for the etiology of obesity and diabetes in the human population. A rat model without this defect would more closely resemble the human condition and thus be more appropriate for the study of diabetic- related conditions and metabolic syndrome. PreClinOmics (PCO) has begun to develop a new rat model without leptin/leptin-receptor defects by crossing a selected rat model with the propensity to develop diabetes with a model that has the propensity to develop obesity. The long-term goal of this project is to create a rat model that will be accepted by biotech and pharmaceutical industries, and the research community to advance the study and development of type II diabetic therapies in humans. Phase I of the project will focus on the continued development, defining, and characterization of the new diabetic rat model. This project has three specific aims. First, continue to develop obese-diabetic strains, as well as an obese non-diabetic strain. Second, test the effects of diet manipulation on the onset and consistency of the phenotypic expression (type II diabetes) in the obese-diabetic rat model. Third, study the effects of a typical anti-diabetic compound on the prevention of diabetes in this model to demonstrate the value of the model in its ability to respond to anti-diabetic compounds. Project Narrative: Current commercially available animal models that are used for obesity and diabetes research and drug development have genetic defects that cause obesity. These defects are not found in the typical obese and diabetic individuals where polygenetic genes seem to be responsible for the condition. The purpose of this project is to develop and produce a new animal model that has polygenetic obesity which develops into diabetes. This should be very important model to develop drugs that will control obesity and adult onset diabetes.

Principal Investigator:

Richard G. Peterson
3178726001
rgp@preclinomics.com

Business Contact:

Joseph Pesek
3178726001
pco@preclinomics.com
Small Business Information at Submission:

PRECLINOMICS, INC.
7918 ZIONSVILLE RD INDIANAPOLIS, IN 46268

EIN/Tax ID: 352145759
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No